Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator

被引:73
|
作者
Cotten, JF
Ostedgaard, LS
Carson, MR
Welsh, MJ
机构
[1] UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242
[2] UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242
[3] UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242
关键词
D O I
10.1074/jbc.271.35.21279
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cystic fibrosis transmembrane conductance regulator (CFTR) contains multiple membrane spanning sequences that form a Cl- channel pore and cytosolic domains that control the opening and closing of the channel. The fourth intracellular loop (ICL4), which connects the tenth and eleventh transmembrane spans, has a primary sequence that is highly conserved across species, is the site of a preserved sequence motif in the ABC transporter family, and contains a relatively large number of missense mutations associated with cystic fibrosis (CF). To investigate the role of ICL4 in CFTR function and to learn how CF mutations in this region disrupt function, we studied several CF-associated ICL4 mutants. We found that most ICL4 mutants disrupted the biosynthetic processing of CFTR, although not as severely as the most common Delta F508 mutation. The mutations had no discernible effect on the channel's pore properties; but some altered gating behavior, the response to increasing concentrations of ATP, and stimulation in response to pyrophosphate. These effects on activity were similar to those observed with mutations in the nucleotide-binding domains, suggesting that ICL4 might help couple activity of the nucleotide-binding domains to gating of the Cl- channel pore. The data also explain how these mutations cause a loss of CFTR function and suggest that some patients with mutations in ICL4 may have a milder clinical phenotype because they retain partial activity of CFTR at the cell membrane.
引用
收藏
页码:21279 / 21284
页数:6
相关论文
共 50 条
  • [31] Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression
    Peters, Kathryn W.
    Gong, Xiaoyan
    Frizzell, Raymond A.
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [32] Cystic fibrosis transmembrane regulator mutations in Hispanic Californians with cystic fibrosis.
    Kharrazi, M
    Alper, O
    Young, S
    Pearl, M
    Graham, S
    Lorey, F
    Sherwin, J
    Wong, LJ
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 413 - 413
  • [33] Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator
    Frauke Mekus
    Manfred Ballmann
    Inez Bronsveld
    Thilo Dörk
    Jan Bijman
    Burkhard Tümmler
    H. J. Veeze
    Human Genetics, 1998, 102 : 582 - 586
  • [34] CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR AND THE ETIOLOGY AND PATHOGENESIS OF CYSTIC-FIBROSIS
    MCINTOSH, I
    CUTTING, GR
    FASEB JOURNAL, 1992, 6 (10): : 2775 - 2782
  • [35] Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease
    Manioudaki, Sofia
    Vasilieva, Larisa
    Mani, Ilianna
    Diamantea, Filia
    Alexopoulos, Theodoros
    Pouriki, Sophia
    Athanassa, Zoe
    Sakagianni, Aikaterini
    Geladari, Eleni
    Elefsiniotis, Ioannis
    Hadziyannis, Emilia
    Alexopoulou, Alexandra
    JOURNAL OF HEPATOLOGY, 2023, 78 : S978 - S979
  • [36] Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy
    Lehr, Carli J.
    Pilewski, Joseph M.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2022, 27 (03) : 198 - 203
  • [37] Cystic fibrosis: bacterial pathogenesis and CFTR (cystic fibrosis transmembrane conductance regulator) modulators
    Vargas-Roldan, Silvia Y.
    Lezana-Fernandez, Jose L.
    Cerna-Cortes, Jorge F.
    Partida-Sanchez, Santiago
    Santos-Preciado, Jose, I
    Rosales-Reyes, Roberto
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2022, 79 (04): : 215 - 221
  • [38] Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis
    Sloane, Peter A.
    Rowe, Steven M.
    CURRENT OPINION IN PULMONARY MEDICINE, 2010, 16 (06) : 591 - 597
  • [39] Cystic Fibrosis Transmembrane Conductance Regulator Mutation Spectrum in Patients with Cystic Fibrosis in Tunisia
    Fredj, Sondess Hadj
    Messaoud, Taieb
    Templin, Carine
    des Georges, Marie
    Fattoum, Slaheddine
    Claustres, Mireille
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2009, 13 (05) : 577 - 581
  • [40] Treatment of Fetal Cystic Fibrosis With Cystic Fibrosis Transmembrane Conductance Regulator Modulation Therapy
    Blumenfeld, Yair J. J.
    Hintz, Susan R. R.
    Aziz, Natali
    Barth, Richard A. A.
    Spano, Jacquelyn M. M.
    El-Sayed, Yasser Y. Y.
    Milla, Carlos
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (07) : 1015 - 1016